Cancer care in Australia
According to World Health Organization comparisons, Australian cancer patients generally have better cancer survival rates than those in other countries.1 In the last 30 years, the death rate for cancer in Australia (number of deaths per 100,000 people) has dropped by more than 24%.2 This trend is driven by treatment improvements and new interventions leading to more patients surviving from the most commonly diagnosed cancers, including bowel cancer and prostate cancer in males and breast cancer in females.3
And yet, Australia has one of the highest rates of cancer diagnosis internationally,4 with 134,000 new cases estimated to be diagnosed in 2018.2 This number is predicted to rise to 150,000 in 2020,2 due to Australia’s increasingly ageing population.5 Currently, an estimated 1.1 million (1 in 22) Australians are living with and beyond a cancer diagnosis.6 By 2040, it is estimated that 1 in 18 Australians will be diagnosed with cancer in their lifetime.6
Healthcare in Australia is largely publicly funded, but cancer patients report relatively high out-of-pocket health costs. The financial costs of cancer in Australia are unequally distributed, as some cancer types are more costly to the individual.7 Those in rural and remote areas often face greater out-of-pocket costs and can have difficulty accessing healthcare services.7
In Australia, cancer has a significant social and economic impact on individuals, families and the broader community. People in lower socioeconomic positions have higher rates of cancer burden, with patients in the lowest socioeconomic group experiencing 1.4 times the cancer burden of those in the highest group.7
The All.Can initiative began in Australia in late 2017, and was officially launched on World Cancer Day (4 February) 2018. The patient-focused initiative aims to gather insights from the cancer community and sharpen the focus on delivery of care truly of value to patients. The Australian chapter plans to identify improvements to the cancer patient care pathway through the healthcare system.
The overarching goal for All.Can is to help contribute to sustainable resource allocation in cancer care so that funding is directed to interventions which create the most value for patients. This reflects the global reforms in healthcare that are moving away from volume-based care and focusing on improving patient outcomes.
All.Can Australia has now entered a new chapter as All.Can Australia Limited, a newly incorporated entity in Australia.
All.Can Australia has proudly been active since 2017. Our achievements to date include:
- 2017: Established a dedicated Steering Committee to represent the initiative and officially launched in Australia on World Cancer Day.
- 2018: Established two key research projects to gather data from the macro level health system perspective and micro level clinical setting about common inefficiencies.
- 2019: Launched the results of the global All.Can patient survey to key stakeholders and media.
- 2020: Finalised the Australian research report, “An exploration of the cancer pathway in Australia”. This marked the publishing of Australia’s first research project to help establish a baseline understanding of the cancer pathway in Australia.
- 2021: Finalised and launched the All.Can Australia Cancer Care Navigator Analysis Report, which outlined the potential benefits of establishing Australia’s first universal cancer care navigation model to patients and the Australian health system.
- 2022: Became a standalone legal entity, All.Can Australia Limited, and pursued pilot opportunities for the Cancer Care Navigator model.
- AIHW. Cancer in Australia 2017; ix: 1039-3307. Available here: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2017/ [accessed: February 2018]
- Cancer Council Australia. Facts and Figures. Available here: https://www.cancer.org.au/about-cancer/what-is-cancer/facts-and-figures.html [accessed: February 2018]
- AIHW. Cancer mortality trends and projections Available here: https://www.aihw.gov.au/reports/cancer/cancer-mortality-trends-and-projections-2014-to-2025 [accessed: February 2018]
- International Agency for Research on Cancer (World Health Organization). Worldwide Cancer Incidence. Available here: http://www.cancerresearchuk.org/sites/default/files/cs_infog_world_inc.pdf [accessed: February 2018]
- Australian Cancer Research Foundation. Cancer incidence and mortality in Australia. Available here: https://acrf.com.au/on-cancer/cancer-statistics-australia/ [accessed: February 2018]
- Cancer Council Australia. Australians living with and beyond cancer in 2040. Available here: https://www.cancerwa.asn.au/resources/2018-01-31-cancer-prevalence-in-2040.pdf [accessed: February 2018]
- AIHW. Burden of cancer in Australia: Australian Burden of Disease Study 2011. Available here: https://www.aihw.gov.au/reports/burden-of-disease/burden-of-cancer-in-australia-australian-burden-of-disease-study-2011/contents/table-of-content [accessed: February 2018]
The All.Can Australia Board is led by representatives from cancer/consumer organisations, biopharmaceutical industry, pharmacists and university faculties.
The aim for All.Can Australia is to reflect the full continuum of cancer care and to have representation that accurately reflects the cancer journey. This is through our Board representation and the third parties we work with.
All.Can Australia is co-chaired by Professor Christobel Saunders and Bill Petch. See below for full details of the All.Can Australia Board, which has been structured to encourage shared decision-making across all activities and is supported by Palin Communications as secretariat.
All.Can Australia Board members
Private Healthcare Australia
The Society of Hospital Pharmacists of Australia
Professor Christobel Saunders
University of Melbourne
Rare Cancers Australia
Australian Healthcare & Hospitals Association
Professor John Zalcberg
Department of Epidemiology and Preventive Medicine, Monash University
All.Can Australia Limited: A new chapter begins for the initiative
Parties urged to back broad cancer care navigation pilot in Tasmania
Australia’s first pan-cancer navigation model delivered by All.Can Australia research
Co-intelligence: Knowledge exchange overtaking competition to drive global cancer care progress
Technology is the missing link to change the future of cancer care
SPCC Webinar Series – 12 April: What is efficiency in cancer care in Australia
All.Can Australia kicks off Cancer Care Navigator Project
All.Can Australia launches national data from patient survey
All.Can Australia has launched the results of the national-level findings from the All.Can international patient survey.
Australia joins international patient survey to improve cancer care
Australians who have been diagnosed and treated for cancer have the opportunity to share their experiences with the world as part of a global research project.
All.Can Australia launches in the lead-up to World Cancer Day
Australia has become the latest country to launch a national All.Can initiative.
Cancer Care Navigator Analysis
Read All.Can Australia’s report on the assessment of the optimal role of cancer care navigators for Australian cancer patients and their families: All.Can Australia – CCN analysis report FINAL.
An Exploration of the Cancer Pathway in Australia
In 2019, All.Can Australia developed a report mapping out the cancer care pathway in Australia through consultations with stakeholders, download All.Can Australia full report here.
Press release: All.Can patient survey findings
- Download All.Can Australia’s full press release on the national-level survey findings: New cancer initiative identifies common ‘pain points’ that impact patient outcomes
Video: Common inefficiencies impacting patient outcomes
Video: Using new research to improve patient outcomes
The All.Can initiative is made up of leading representatives of patient organisations, policymakers, healthcare professionals, science and industry. All the publications produced under the initiative reflect the consensus of All.Can Australia Board members who have full editorial control.
All.Can Australia is funded by Bristol Myers Squibb Australia, with support from Palin Communications as secretariat.